









Markets
/
Stocks
/
nasdaq-supn
/

Supernus Pharmaceuticals Inc

SUPN

45.765USD

+0.965+2.15%

Market hours （ET）Quotes delayed by 15 min

2.57BMarket Cap

39.82P/E TTM



Supernus Pharmaceuticals Inc

45.765

+0.965+2.15%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

3 / 175

Overall Ranking

46 / 4723

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

43.800

Target Price

-0.43%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 21.67.

Fairly Valued

The company’s latest PE is 38.41, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 63.61M shares, decreasing 3.80% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 6.19M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.95.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 9.00, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 165.45M, representing a year-over-year decrease of 1.71%, while its net profit experienced a year-over-year decrease of 12.97%.

Score

Industry at a Glance

Previous score

9.00

Change



Financials

8.42

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.67

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.37

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.57

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 4.08, which is higher than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 38.41, which is 26.97% below the recent high of 48.77 and 19.52% above the recent low of 30.92.

Score

Industry at a Glance

Previous score

4.12

Change

-0.04

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 3/175

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 7.60, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Supernus Pharmaceuticals Inc is 45.00, with a high of 46.00 and a low of 40.00.

Score

Industry at a Glance

Previous score

7.60

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

43.800

Target Price

-0.43%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Supernus Pharmaceuticals Inc

SUPN

Biogen Inc

BIIB

Amgen Inc

AMGN

Alnylam Pharmaceuticals Inc

ALNY

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 8.72, which is higher than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 47.13 and the support level at 42.13, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.14

Change

1.58

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.968

Neutral

RSI(14)

58.156

Neutral

STOCH(KDJ)(9,3,3)

33.389

Neutral

ATR(14)

1.082

Low Volatility

CCI(14)

-76.678

Neutral

Williams %R

59.342

Sell

TRIX(12,20)

0.528

Sell

StochRSI(14)

20.204

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

44.980

Buy

MA10

45.439

Buy

MA20

44.952

Buy

MA50

39.905

Buy

MA100

36.066

Buy

MA200

35.533

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 113.46%, representing a quarter-over-quarter decrease of 1.94%. The largest institutional shareholder is The Vanguard, holding a total of 6.19M shares, representing 11.04% of shares outstanding, with 0.29% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

8.20M

-3.50%

The Vanguard Group, Inc.

Star Investors

6.15M

+0.21%

Armistice Capital LLC

5.20M

+7.44%

Dimensional Fund Advisors, L.P.

2.90M

+0.87%

Macquarie Investment Management

2.70M

+2.69%

State Street Global Advisors (US)

2.15M

-1.96%

Khattar (Jack A)

2.01M

Renaissance Technologies LLC

Star Investors

1.59M

-0.81%

Stephens Investment Management Group, LLC

1.74M

-0.78%

Geode Capital Management, L.L.C.

1.33M

-12.18%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 5.71, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.77. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.